Use of disease embedding technique to predict the risk of progression to end-stage renal disease

Fang Zhoua, Avrum Gillespieb, Djordje Gligorijevic, Jelena Gligorijevic, Zoran Obradovic⁎

a School of Data Science & Engineering, East China Normal University, Shanghai, China
b Division of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States
c Center for Data Analytics and Biomedical Informatics, Temple University, Philadelphia, PA, United States

ARTICLE INFO

Keywords:
Low-dimensional disease representation
Disease progression
Unsupervised learning
Electronic health records
Chronic Kidney Disease
End Stage Renal Disease

ABSTRACT

The accurate prediction of progression of Chronic Kidney Disease (CKD) to End Stage Renal Disease (ESRD) is of great importance to clinicians and a challenge to researchers as there are many causes and even more comorbidities that are ignored by the traditional prediction models. We examine whether utilizing a novel low-dimensional embedding model disease2disease (D2D) learned from a large-scale electronic health records (EHRs) could well clusters the causes of kidney diseases and comorbidities and further improve prediction of progression of CKD to ESRD compared to traditional risk factors. The study cohort consists of 2,507 hospitalized Stage 3 CKD patients of which 1,375 (54.8%) progressed to ESRD within 3 years. We evaluated the proposed unsupervised learning framework by applying a regularized logistic regression model and a cox proportional hazard model respectively, and compared the accuracies with the ones obtained by four alternative models. The results demonstrate that the learned low-dimensional disease representations from EHRs can capture the relationship between vast arrays of diseases, and can outperform traditional risk factors in a CKD progression prediction model. These results can be used both by clinicians in patient care and researchers to develop new prediction methods.

1. Introduction

The rapid growth of electronic health records (EHRs) from multiple sources has led to an increased interest in utilizing EHRs for improving clinical research, decision-making, and patient management [1]. EHRs contain patient information collected over time including diagnostic findings, procedures, medications, and patients' demographic information. Such a rich source of patient-specific data often contains sparse, noisy, heterogeneous and incomplete information. Furthermore in the EHRs, diseases are typically encoded using ICD-9 (International Classification of Diseases, Ninth Revision) or ICD-10 coding. These codes are treated as atomic units and lack the notion of similarity between diseases, even though codes do have a hierarchical structure.

Chronic Kidney Disease (CKD) is a progressive condition which is caused by a heterogeneous assortment of diseases and is associated with multiple comorbidities which can contribute to the progression of the kidney disease. As a result of this heterogeneity, existing predictive methods for progression of Chronic Kidney Disease (e.g. [2–5]) typically are either based on a few demographic factors and lab parameters or require intensive supervision from domain experts, and miss out on the advantage of encoding progression based on the latent knowledge hidden in the observed EHRs. Therefore, data-driven context-aware approaches that can effectively analyze EHR data are required to obtain insights for improving the quality of health-care.

In this work, we developed a new framework for predicting the risk of progression from stage 3 chronic kidney disease (CKD) to the end-stage renal disease (ESRD) within three years based on the diseases that co-occur with (or occur before) the diagnosis of stage 3 CKD. The accurate prediction of progression of stage 3 CKD to ESRD is of great importance as a large portion of patients that have CKD [6,7] will not progress to ESRD. ESRD carries a high morbidity and mortality [8]. Understanding which patients are at high risk of progression is important for appropriate referral, accurate prognosis, discussion, and timely planning for renal replacement therapy (RRT) [9,10]. Furthermore, improved prediction can help identify patients who may benefit from interventions to slow progression [11].

People with stage 3 CKD have multiple comorbidities that co-occur with (or occur before) the diagnosis of stage 3 CKD [12]. Although

⁎ Corresponding author.
E-mail address: zoran.obradovic@temple.edu (Z. Obradovic).

https://doi.org/10.1016/j.jbi.2020.103409
Received 29 August 2019; Received in revised form 18 March 2020; Accepted 19 March 2020
Available online 15 April 2020
1532-0464/ © 2020 Elsevier Inc. All rights reserved.
many of these comorbidities are redundant, there is a significant diversity among them. This heterogeneity represents a challenge for prediction models. Different from the work of feature selection that aims to find a smaller set of variables, we explored how to summarize all of the discrete diagnosis ICD-9 codes, both the redundant ones as well as the heterogeneous ones, by considering their semantic information. Motivated by recent work that learns disease phenotyping through a distributed, neural embedding model [13] from EHRs, we applied disease2disease [13] model to learn a low-dimensional continuous representation for each disease, and clustered diseases based on learned representations, treating the collections of clusters as generated variables, and then transformed hospitalization records to predictors’ space.

The objective of the present study is to develop and validate a simple but accurate prediction model that automatically generates a compact set of interpretable variables from EHRs. The generated variables contain approximately the same information of the original set of comorbidities of stage 3 CKD. We analyzed the impact of the generated variables through a logistic regression model (binary outcomes) and a cox proportional hazard model (time to ESRD).

The proposed framework can be generalized to other chronic diseases, as the disease representations are learned from EHRs that are independent of a specific disease. Besides, the variables generated by the proposed approach are easy to interpret, as they represent groups of diseases. Since the generated variables summarizes the information of relevant diseases, the dimension of variables was highly reduced which is of high importance for applicability of the proposed methodology in real-world systems where predictions will need to be reviewed by the physicians on a case-to-case basis.

2. Background and significance

2.1. CKD progression prediction

ESRD is a devastating disease that is associated with a high morbidity and mortality for the patient and puts a significant financial burden on the health-system [14]. While it is estimated that over 28 million people have CKD, less than 1% develop ESRD every year [8], this makes it challenging for nephrologists and health care providers to have appropriate discussions around treatment and prognosis, likely leading to both overtreatment of non-progressors and under-treatment of progressors [15].

Previous prediction models [2,16,17] have primarily focused on laboratory values and basic demographic data routinely collected in a patient visit. These are well-standardized and are easier to model rather than the heterogeneous diseases that cause CKD, both systemic and renal-limited, and the myriad of comorbidities found in these patients [12]. Furthermore, non-renal comorbidities and those that are a consequence of or exacerbated by kidney disease, may contribute to the progression of kidney disease [18].

This work takes advatange of EHRs to examine CKD patients’ comorbidities. Many CKD patients have Diabetes Mellitus (DM), Hypertension (HTN) and Peripheral Vascular Disease (PVD) [12,19] and are at increased risk of hospitalization for stroke and myocardial infarction. During these hospital stays, these comorbidities are routinely coded. This study aims to incorporating CKD comorbidities to better predict which patients are at risk for progression to ESRD.

2.2. Medical concepts representations

Learning meaningful representations of medical concepts (diseases, procedures, medications, etc.) has been an important aspect of data-driven approaches in healthcare and medicine. Notable approaches include building disease comorbidity graphs [20,21], formulating EHRs as temporal matrices [22] or even tensors [23] of medical events for each patient and finally representing them using the neural families of models [13,24,25]. The direction that yielded most advancements and improvements are the neural families of models, in particular models for learning neural distributed representations of medical concepts [13,25–27]. They have been shown to perform very well on a variety of tasks, from computational phenotyping [24], to estimating hospital quality indicators [28], and predicting patient mortality risk [29]. The focus of this study is not to develop a new disease embedding technique, instead, we aim to use these quality embeddings and compare them against expert level features for the important task of modeling disease progression.

3. Method

Unlike traditional methods [3,16], which select well-established factors based on domain knowledge or prior experience as predictors for disease progression, our approach works in an unsupervised manner, without relying on explicit knowledge of domain expert. The framework of the proposed approach is shown in Fig. 1. The first step: learning the embedded representations of all diagnosis ICD-9 codes by applying the model disease2disease (D2D) [13] on the whole dataset. Each discrete ICD-9 code is assigned a low-dimensional continuous vector. The second step: clustering the comorbidities of stage 3 CKD based on vector similarity in the embedded space. A clustering algorithm, such as hierarchical clustering, is applied, and the obtained clusters are taken as candidate predictors. The list of comorbidities of stage 3 CKD filled with redundant information is summarized into K compact groups. Each group contains comorbidities that often co-occur and comorbidities that with similar neighboring diseases. The third step: transforming inpatients’ hospitalization records into predictors’ space. The resulting matrix (colored in orange in Fig. 1) can be used to train any classifier. The descriptions of these three steps are in Sections 3.1,2,3.3.
diseases in patients’ EHR ordered by the time of diagnosis

Fig. 2. Graphical summary of the D2D approach projecting a central disease to surrounding ones \(d_{i-3}, ... , d_i, d_{i+1}, ... , d_{i+3}\) from a discharge record.

3.1. Low-dimensional embedding model

We applied the D2D approach [13] (shown in Fig. 2) to learn disease representations in a low-dimensional space. D2D builds on the idea of a distributed language model word2vec [30] in Natural Language Processing (NLP), where the goal is to produce a low-dimensional continuous vector space in which each unique word is assigned a corresponding vector in the space.

The D2D approach adapted the word2vec algorithm to learn disease representations using EHRs. It treats diseases in EHRs as words, and each patient’s hospitalization record that contains a sequence of ordered diseases as the context of the disease in the record. Let \(P\) represent a set of inpatient care records and \(D\) denote a set of possible diseases in the records \(P\). A record \(p\) \(\in P\) contains a sequence of diseases, that is, \(p = (d_1, ..., d_i) \subset D\). The goal of D2D approach is to learn representations of diseases \(D\) in a low-dimensional space by maximizing the objective function \(L\) over the entire set of records \(P\), that is,

\[
L = \sum_{p \in P} \sum_{d_m \in P} \sum_{b \in B} \log P(d_m|d_m),
\]

where \(d_{m+1}\) represents the neighboring disease of the given disease \(d_m\), and \(B\) is the length of the context of disease \(d_m\). The probability distribution \(P(d_m|d_m)\) is defined using the softmax function, that is,

\[
P(d_{m+1}|d_m) = \frac{\exp(\nabla^T v'_{d_m} v'_{d_{m+1}})}{\sum_{d_{m+1}} \exp(\nabla^T v'_{d_m} v'_{d_{m+1}})}.
\]

where \(v_i\) and \(v'_j\) are input and output vector representation of disease \(d\), and \(v'_j\) is the transpose of \(v_j\). \(|D|\) represents the size of unique diseases in the set of records \(P\). The probability is calculated for \(b\) diseases surrounding the \(i\)th disease \(d_i\), as shown in Fig. 2, and the entire process is repeated in a sliding window manner capturing context of entire hospitalization record. Ultimately, diseases which have similar neighbourhoods will be embedded closer in the learned space. Since \(|D|\) is very large, the training process of approximating disease vectors becomes computationally expensive. To address the training process computation time, we have employed the negative sampling technique [31].

3.2. Distance between diseases

Once the low-dimensional embedded disease representations are learned, the similarity between any two diseases is calculated by using cosine similarity, that is,

\[
sim(v_{d_i}, v_{d_k}) = \frac{v_{d_i}^T v_{d_k}}{\|v_{d_i}\| \|v_{d_k}\|}.
\]

The range of \(\sim(v_{d_i}, v_{d_k})\) is \([-1, 1]\). Diseases that have similar contexts (similar comorbidity patterns) will have a larger similarity score even if they do not co-occur in the same hospitalization record, while diseases that show different comorbidity patterns (i.e. diseases that tend not to be diagnosed together) will have lower similarity score.

3.3. Transforming hospitalization records into predictors’ space

Assuming diseases are clustered in \(K\) groups \(G_1, ..., G_K\), the corresponding predictors are \(f_1, ..., f_K\). Let \(c_i\) represent the center point of the cluster \(G_i\) \((k \in K)\). The embedded representation of \(c_i\) is the averaged vector of diseases belonging to the cluster \(G_i\), that is, \(v_{c_i} = \frac{1}{|G_i|} \sum_{d_m \in G_i} v_{d_m}\). Next, we present one way to transform the hospitalization records \(P_i\) of the \(i\)th inpatient into predictor space, which calculates how similar the diseases in inpatient records \(P_i\) are to center clusters.

The \(i\)th inpatient’s hospitalization records \(P_i\) is a set of records which contains \(t\) previous hospitalization records of the \(i\)th inpatient and the record \(p\) that contains the stage 3 CKD diagnosis, that is, \(P_i = \{p_1, p_2, ..., p_t\}\). \(P_e\) denotes the \(e\)th record that was prior to the record \(p\). The diagnosed diseases of the \(i\)th inpatient, except stage 3 CKD, are the union of diseases in the records \(P_i\). Given the \(i\)th inpatient’s hospitalization records \(P_i\), the value of the generated predictor \(f_k\) is defined as the maximum similarity among similarities between the individual diagnosed disease in \(P_i\) and the center point \(c_i\).

\[
f_k(P_i) = \max_{d_m \in P_i} \sim(v_{d_m}, v_{c_i}) \text{, } \sim(v_{d_m}, v_{c_i}) > 0.
\]

For each diagnosis code \(d_m\) in the records \(P_i\), if \(d_m\) belongs to the group \(G_k\), then the similarity between \(d_m\) and \(c_i\) is calculated based on the Eq. (3). If \(\sim(v_{d_m}, v_{c_i}) < 0\), it will be discarded. Note that if none of disease codes in the records \(P_i\) belong to the cluster \(G_k\), then the value of the generated predictor \(f_k(P_i)\) is 0. An illustrated example is shown in Fig. 3. Using the maximum similarity to compute predictors’ values will result in a sparse matrix.

![Fig. 3. An illustrated example of transforming an inpatient’s records into predictors’ space.](image-url)
### 4. Experiment

#### 4.1. Study population

The study cohort was derived from the State Inpatient Database\(^1\) (SID) provided by the Healthcare Cost and Utilization Project (HCUP), containing inpatient care records in California. In total, there are 35,844,800 discharge records from 474 hospitals over a period of 9 years (from January 2003 to December 2011). Each patient record contains up to 25 ICD-9 codes, as well as the patients' demographic information, such as gender, age and race.

We selected inpatients who satisfied two conditions: (1) have a hospitalization record that contains stage 3 CKD diagnosis (ICD-9 585.3); (2) have at least 3 records, prior to the initial CKD 3 record, that do not contain stage 3 CKD diagnosis. The start of observation was the date of the initial record that contains stage 3 CKD diagnosis. Patients were censored at the earliest of death or the last record of a visit in SID. The observation time for each patient was computed as the number of days between the start of observation and the end date. We further selected two groups of inpatients. The first group (high-risk cohort) contains 1,375 inpatients who were later diagnosed with ESRD (ICD-9 585.6) within 3 years. The second group (low-risk cohort) consists of 1,132 inpatients whose CKD remains at stage 3 for more than 3 years. The demographic information of inpatients is shown in Table 1. The age information is the one recorded at the start of observation time.

#### 4.2. Experimental setup

We first applied D2D approach\(^2\) to more than 35 million inpatient records in the SID to obtain the learned representations of all diseases, and then considered two scenarios to generate variables. **Scenario 1:** Clustering comorbidities of stage 3 CKD into K groups. The number of comorbidities being clustered is 2,135. The assumption is that CKD comorbidities are more relevant to the CKD progression. **Scenario 2:** Clustering diseases that are present in up to 3 previous records into K groups. The rationale of choosing up to three previous records is that inclusion of more than three previous records does not significantly improve prediction accuracy\(^3\). The number of diseases increased to 3,281.

We applied hclust (R function, parameter “method” is set as “average”) to perform a hierarchical cluster analysis for the diseases. The cluster number K is determined through Davies-Bouldin index\(^4\), which is an internal evaluation metric to measure the quality of the clustering. A group of clusters with a small Davis-Bouldin index is considered as a good clustering result. We used clusterCrit R package\(^5\) to compute the Davis-Bouldin index, and set K as 58 for Scenario 1 and K as 92 for Scenario 2.

---

Table 2
Independent variables for the five models.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Model_1</th>
<th>Model_2</th>
<th>Model_3</th>
<th>Model_4</th>
<th>Our model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Gender</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Lab variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-OH Vitamin D</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Potassium</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Sodium</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Total Protein</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Parathyroid Hormone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine Protein Creatinine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uric Acid</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Causes of ESRD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Secondary GN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interstitial Nephritis</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hypertension</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cystic, Hereditary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neoplasms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscellaneous Conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICD-9 codes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clusters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a BUN, Chloride, Magnesium, and Phosphate are not included, as ICD-9 codes could not distinguish the low or high values of these variables.

Table 3
The classification accuracy (mean ± standard deviation) of the five models from logistic regression. K represents the number of predictors used.

<table>
<thead>
<tr>
<th>Records used</th>
<th>The proposed model</th>
<th>Model_4</th>
<th>Model_1</th>
<th>Model_2</th>
<th>Model_3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scenario 1 (K = 58)</td>
<td>0.68 ± 0.05</td>
<td>0.69 ± 0.05</td>
<td>0.70 ± 0.06</td>
<td>0.61 ± 0.05</td>
<td>0.65 ± 0.05,b</td>
</tr>
<tr>
<td>Scenario 2 (K = 92)</td>
<td>0.68 ± 0.04</td>
<td>0.69 ± 0.05</td>
<td>0.70 ± 0.07</td>
<td>0.61 ± 0.05</td>
<td>0.66 ± 0.05,b</td>
</tr>
<tr>
<td>[p]</td>
<td>0.68 ± 0.05</td>
<td>0.71 ± 0.05</td>
<td>0.69 ± 0.05</td>
<td>0.61 ± 0.06</td>
<td>0.66 ± 0.05</td>
</tr>
<tr>
<td>[p_l, p]</td>
<td>0.69 ± 0.07</td>
<td>0.68 ± 0.04</td>
<td>0.68 ± 0.05</td>
<td>0.55 ± 0.06</td>
<td>0.64 ± 0.05</td>
</tr>
<tr>
<td>[p_l, p, p_l, p]</td>
<td>0.66 ± 0.04</td>
<td>0.67 ± 0.05</td>
<td>0.69 ± 0.04</td>
<td>0.55 ± 0.04</td>
<td>0.64 ± 0.06</td>
</tr>
<tr>
<td>[p_l, p, p_l]</td>
<td>0.66 ± 0.05</td>
<td>0.68 ± 0.05</td>
<td>0.70 ± 0.05</td>
<td>0.55 ± 0.05</td>
<td>0.63 ± 0.06</td>
</tr>
<tr>
<td>[p_l, p, p_l, p, p_l]</td>
<td>0.67 ± 0.04</td>
<td>0.68 ± 0.06</td>
<td>0.70 ± 0.05</td>
<td>0.55 ± 0.04</td>
<td>0.62 ± 0.06</td>
</tr>
</tbody>
</table>

b The accuracy obtained from Scenario 1 is more accurate (p-value < 0.05) than the one obtained by the compared model.

5.3. An analysis of variables

We applied a cox proportional hazards model to study the association between the individual variables and time to ESRD. Since the number of variables in Model_4 is more than two thousands and the proposed model well summarizes the information of all comorbidities in the Model_4 (see. Section 5.2), we focus on studying the variables in Model_1, Model_2, Model_3 (Table 4) and the proposed model (Table 5). Table 4 shows the log hazard ratios of variables that significantly predict progression to ESRD in the Model_1, Model_2 and Model_3 respectively. In all three models, younger age and male gender (gender variable is set 0 for male, and 1 for female) were associated with increased risk of progression.
In the Model_2, laboratory variables associated with a higher risk of progression from stage 3 to ESRD include low value of Bicarbonate ($p$-value < 0.001), low value of Hematocrit ($p$-value < 0.001), low value of Protein ($p$-value = 0.002), high value of Parathyroid Hormone ($p$-value = 0.002), high value of Potassium ($p$-value < 0.001) and high value of Uric Acid ($p$-value < 0.001). Furthermore, Glomuleronephritis ($p$-value < 0.001) and Neoplasms ($p$-value < 0.001) were found to be associated with higher risk of progression to ESRD. Younger age was still statistically significantly associated with the target variable.

In the Model_3, besides those laboratory variables which were identified associated with risk by the Model_2, the Model_3 found the elevated levels of Calcium ($p$-value = 0.03) and Sodium ($p$-value = 0.04) were associated with increased risk of CKD progression. Furthermore, Glomuleronephritis ($p$-value < 0.001) and Neoplasms ($p$-value = 0.006) were found to be associated with higher risk of progression.

Table 5 presents the clusters generated by our model that statistically significantly predict progression to ESRD. Younger age was still associated with increased risk of progression; however, gender variable was not statistically significantly associated with the target variable. The following clusters were associated with increased risk of progression: GN (Glomerulonephritis) and Organ TX (Transplant) (C_0), Diabetes (C_1), HTN (Hypertension) (C_11), BMI (Body Mass Index) (C_14), Anemia and GI (Gastrointestinal) (C_2), Hematocrit and DNR (Do Not Resuscitate Code) (C_41), Multiple Myeloma (C_43), Sepsis (C_5), Cirrhosis (C_9). The following clusters were associated with decreased risk of progression: Obesity and Sleep Apnea (C_12), Spine and Nerve (C_15), Hips, Eyes and Skin (C_16), Thyroid (C_22), Psychiatric (C_24), Benign Gyn (Gynecologic) and Family Hx (history) (C_28), Asthma (C_29), Hematuria2 and Hematologic (C_6).

6. Discussion

We have developed a novel CKD progression prediction model which clusters the causes of kidney diseases and the multiple comorbidities that affect people with kidney disease. This represents an advancement to previous prediction models that were based on demographic characteristics and laboratory parameters. Based on our framework we can predict which CKD patients are at high risk for progression to ESRD after a hospital admission and may benefit from intensive follow-up. Additionally, healthcare providers can use this predictive model to help tailor discussions with patients about their risk for CKD progression and the chances of developing ESRD.
Previous prediction models have relied heavily upon laboratory parameters and have treated them as individual risk factors in a traditional Cox proportional-hazards model [2,3,16,17,37]. Quantifying and incorporating the multiple comorbidities that are associated with CKD is challenging, because patients with chronic kidney disease tend to have the highest number of comorbidities and complexity [38]. Using unsupervised learning, the proposed model was able to identify clusters of causes of kidney diseases that were associated with progressive kidney disease and well summarized the information of CKD comorbidities (see Table 3). The proposed model highly reduced the dimension of comorbidities, which helps clinicians more easily interpret the prediction results. Furthermore, this cluster of heterogeneous disease outperformed modeling the diseases using the specification currently accepted designation of the CMS 2728 (Centers for Medicare and Medicaid Services form 2728, which is the ESRD medical evidence report medicare entitlement). This model not only allows for the prediction of progression of CKD at the patient-level, but also identifies classic and novel comorbidities associated with progression of CKD which are potentially modifiable and may lead to new biologic discoveries.

One such novel cluster was the C_0 which identified patients with solid organ transplants both renal and otherwise. These patients had a high risk of progressing to ESRD if they were admitted to the hospital with CKD. They were in the same cluster of chronic glomerulonephritis which has been shown to have a high risk of progression [39]. It is unclear whether this solely related to the side effects of calcineurins [40], the diseases that caused the organ failure, or comorbidities associated with solid organ transplant. Additionally, this cluster can be used to predict three year allograft survival in patients with renal transplants and stage 3 CKD, which has been a challenge using traditional models [37].

Clusters that contained Diabetes Mellitus type 1 and 2 (C_1), severe hypertension (C_11) [2] and anemia (C_2) [4] were associated with a high risk of progression. Clusters with severe sepsis and acute kidney injury (C_5) [41], multiple myeloma and pathological fracture (C_43) [42], and cirrhosis predicted a high risk of progression (C_9) [43]. This clustering method however did not differentiate between hepatorenal syndrome and glomerulonephritis associated with the viral hepatitis [44]. The disease clusters are useful for practitioners to identify which patients will require close follow-up.

The clustering method also identified clusters that predicted non-progression of CKD. Several of these clusters were associated with older age and female sex. Clusters 15 (spine and nerve) as well as 16 (hip, eyes, and skin) were conditions related with older age whereas cluster 28 was female specific as it mostly contained gynecological diagnoses. This may explain why including age and sex variables improved the performance of alternative models but did not improve the performance of the proposed model, as age and sex information were already represented by clusters. This in turn shows the superiority of the proposed model when some sensitive information of patients, such as age and gender, are missing. Older patients tended to be in the non-progression cohort and may not have had true progressive CKD but rather age-related nephron loss [45]. This finding of gynecological problems being associated with a low risk of progression was reported in an article [4] that applied a LDA (Latent Dirichlet allocation) model to analyze the texts of CKD patients medical charts. The cluster (C_22) associated with thyroid disease predicted non-progression, there CKD may be a result of decrease glomerular filtration rate (GFR) from hyperthyroidism that improves with thyroid hormone replacement [46]. Asthma and viral pneumonias (C_29) predicted non-progression which is also similar to the findings of Perotte et al. [4]. Patients with asthma and viral pneumonia were likely not as ill as the patients with sepsis and respiratory failure. Of note, while psychiatric illness is common among patients with advanced CKD and ESRD [47], the psychiatric diagnoses (C_24) are not predictive of progressive disease. Future research should focus on how to integrate mental health care and CKD/ESRD care.

The goal of the paper was to find clusters of diagnoses associated with CKD progression and not to identify plausible biologically interpretable risk factors. That being said our method has grouped patients that progress rapidly and represent areas of future mechanistic research. For example, why are some patients who are on calcineurin inhibitors progress rapidly while others do not? Perhaps there is a genetic link to other glomerulonephritides. Another area of research is why some clusters such as autoimmune thyroiditis, Spondylarthopathies, and giant cell arteritis were associated with a low risk of progression. Future work should improve disease representations by integrating biological information, such as the association between diseases and genes (and proteins).

Although there is a current trend for disease phenotyping using the EMR and disease coding, we noticed some inherent problems of using ICD-9 coding as the same apparent disease can be coded differently and is subject to the bias of the person entering the ICD-9 code. For example, in the clustering model, hematuria that clusters with patient being overweight and restrained and refusing care (C_41) predicted progressive CKD, however, an older code for hematuria associated with hematologic diagnoses (C_6) predicted non-progressive CKD. This discrepancy may reflect that the latter group had non-glomerular hematuria [48]. Not only did a diagnosis for being overweight appear in the aforementioned hematuria cluster (C_41), but also in a cluster associated with sleep apnea (C_12) and a cluster associated with actual measurement of BMI (C_14). While glomerular disease associated with obesity and hypoxia has been previously described [49], it is not captured in this cluster. Furthermore, our findings reflect the corpus of literature which doesn’t always find an association with being overweight/obese and progressive kidney disease [50]. Lastly, diabetic retinopathy was clustered with other ophthalmologic conditions (C_16) and was associated with non-progressive CKD. While there is a strong association with diabetic retinopathy and diabetic nephropathy, this cluster may represent the subset that do not have diabetic nephropathy [51], the coding is better. Another possible explanation is that since they are getting ophthalmologic care, they are getting other preventive care that slows the progression of their kidney disease.

Our framework has several other limitations. While we used a large state hospital database to examine over 2000 comorbidities it is possible we missed patients that rely only on ambulatory or outpatient care or were only hospitalized once before the diagnosis of ESRD. Using only hospital records, we may be oversampling patients that are more ill and are frequently hospitalized or have barriers to receiving outpatient care. We also are missing patients that had no medical care before the diagnosis of ESRD. These patients probably represent a small proportion of the whole as CKD patients tend to be disproportionately hospitalized [52]. Another limitation is that the proposed model did not use direct laboratory measurements. That being said, the diagnoses hyperkalemia, secondary hyperparathyroidism and anemia are diagnoses based on lab parameters that are known to be predictors of progression [16] and were part of clusters associated with progressive kidney disease. Finally, whenever examining medical record data there is always a chance for incorrect coding [53].

The advantage of this study was that it used records from a large hospital system. This gave us the ability to develop unique disease clusters. The data is publicly available and the model can be replicated. Even though this work focused on CKD progression, our model can be applied to other disease progression problems (e.g. [29,54]). Research is necessary to see if the model can be improved with outpatient data, including individual measurements such as blood pressure as well as subjective measurements. Additionally, future research is needed to
examine whether the increased specificity of ICD-10 codes improves prediction.

Credit authorship contribution statement


Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This research was supported in part by the Pennsylvania Department of Health Cure Health Data Science Research Project, NSFC grant 61902127, Natural Science Foundation of Shanghai Department of Health CURE Health Data Science Research Project, and NIH NIDDK K23 DK11194.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.jbi.2020.103409.

References


